Extended Anticoagulation With Rivaroxaban for Cancer-Associated Low-Risk Pulmonary Embolism by P

27 Feb 20265 min read0 viewsJournal Feed

GIST (Key Takeaways)

Journal of the American Heart Association, Volume 15, Issue 6 , March 17, 2026. Background.
The ONCO PE (Optimal Duration of Anticoagulation Therapy for Low‐Risk Pulmonary Embolism Patients With Cancer) trial demonstrated the superiority of 18‐month compared with 6‐month rivaroxaban treatment for cancer‐associated low‐risk pulmonary embolism in reducing recurrent venous thromboembolism. However, it was uncertain whether the results could be applicable to patients with different performance status (PS) scores, which evaluate the physical condition of patients with cancer undergoing anticancer treatment.
Methods. In this post hoc subgroup analysis of the ONCO PE trial, we compared the 18‐month and 6‐month rivaroxaban treatment groups in 2 subgroups: the low PS score (no restricted physical activity: PS=0; n=79) and high PS score (restricted physical activity: PS ≥1; n=99) subgroups.

Clinical Editorial

Journal of the American Heart Association published a clinical update in Cardiology on 27 Feb 2026.

The item focuses on Extended Anticoagulation Therapy With Rivaroxaban for Cancer‐Associated Low‐Risk Pulmonary Embolism According to Different Performance Status Scores: Insights From the ONCO PE Randomized Trial.

Review the original article for the full source wording and details.